Cleveland Clinic has joined the PATHFINDER Study, a prospective, multi-center clinical trial that is evaluating the clinical use of an investigational blood test that has the ability to detect more than 50 cancers across stages I-IV with a single blood draw. The test aims to detect cancers in earlier stages that otherwise may not be detected until symptoms appear, when the chances of survival are lower. PATHFINDER is the first trial to study implementation of the blood test into clinical practice. To learn more, visit Clevelandclinic.org/pathfinderstudy.
MEDIA CONTACTRegister for reporter access to contact details